A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases

被引:8
作者
Naredi, P
Öman, M
Blind, PJ
Lindnér, P
Gustavsson, B
Hafström, L
机构
[1] Univ Umea Hosp, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, S-41345 Gothenburg, Sweden
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2003年 / 29卷 / 05期
关键词
liver metastases; colorectal cancer; intraarterial infusion; 5-fluorouracil;
D O I
10.1016/S0748-7983(03)00002-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: A prospective randomized study was executed comparing two regimens of regional therapy for liver metastases from colorectal cancer. Methods: Eighteen patients were allocated to hepatic artery occlusion for 16 h followed by intraportal 5-fluorouracil (5-Fu) infusion (1000 mg/m(2)) for 5 days every sixth week (HAO). Twenty-one patients received intra-arterial 5-Fu infusion + Leucovorin (100 mg) i.v. for 2 days every second week (HAI). The follow up every third month included CT and CEA. Thirteen patients had limited extrahepatic cancer. At tumor progression regional therapy was stopped and systemic chemotherapy or the best supportive care was administered. Results: The study was discontinued after randomization of 39 patients. No significant difference in survival within patients with and without extrahepatic cancer was present. The mean survival was longer in the HAI group than for the HAO group (19 months versus 13 months, p = 0.0 147) (median 18 (8-37) versus 12 (2-26). PR and SID were registered in 8/18 in the HAO group and 17/21 patients in HAI group. The median time to progress was 4 (1-22) months versus 7 (1-23) months for the HAO and HAI group, respectively. Conclusion: Regional intraarterial infusion with 5-Fu gives significantly better survival than hepatic artery occlusion followed by portal infusion. A limited amount of extrahepatic cancer does not influence survival time. A trial comparing hepatic artery 5-FU infusion and Leucovorin versus the most effective systemic therapy is warranted. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:459 / 466
页数:8
相关论文
共 16 条
[1]   QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES [J].
ALLENMERSH, TG ;
EARLAM, S ;
FORDY, C ;
ABRAMS, K ;
HOUGHTON, J .
LANCET, 1994, 344 (8932) :1255-1260
[2]   Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients [J].
Bensmaïne, MA ;
de Gramont, A ;
Brienza, S ;
Marty, M ;
Lévi, F ;
Ducreux, M ;
François, E ;
Gamelin, E ;
Bleiberg, H ;
Bleuzen, P ;
Simon, J ;
Cvitkovic, E .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) :2335-2343
[3]  
Buyse M, 1996, J NATL CANCER I, V88, P252
[4]   A PROSPECTIVE RANDOMIZED TRIAL OF REGIONAL VERSUS SYSTEMIC CONTINUOUS 5-FLUORODEOXYURIDINE CHEMOTHERAPY IN THE TREATMENT OF COLORECTAL LIVER METASTASES [J].
CHANG, AE ;
SCHNEIDER, PD ;
SUGARBAKER, PH ;
SIMPSON, C ;
CULNANE, M ;
STEINBERG, SM .
ANNALS OF SURGERY, 1987, 206 (06) :685-693
[5]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[6]  
HAFSTROM L, 1986, ANN CHIR GYNAECOL FE, V75, P85
[7]  
HAFSTROM L, 1994, CANCER, V74, P2749, DOI 10.1002/1097-0142(19941115)74:10<2749::AID-CNCR2820741003>3.0.CO
[8]  
2-M
[9]  
Harmantas A, 1996, CANCER, V78, P1639, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1639::AID-CNCR1>3.0.CO
[10]  
2-9